• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Topics in Cardiometabolic Disease: Hypertension Guideline Quiz

Slideshow

Cardiometabolic disease affects 1 out of every 2 Americans today. This first of 4 quizzes tests your knowledge of how to manage hypertension, heart failure, and renal disease.

Currently 1 out of 2 American adults is living with one or more cardiometabolic diseases.

Cardiometabolic disease is a cluster of interrelated metabolic dysfunctions that leads to chronic and frequently fatal conditions including cardiovascular diseases, such as coronary heart disease, stroke, and hypertension, as well as metabolic diseases, such as type 2 diabetes, obesity and non-alcoholic fatty liver disease.

Find out what you know about guideline recommendations surrounding hypertension, heart failure, and renal disease in Quiz #1 in our series of 4 on cardiometabolic disease.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
More than Half of US Adults May Be Eligible for Semaglutide Therapy / image credit Dhruv Kazi, MD, MSc, MS Smith Center for Outcomes Research in Cardiology

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

Grace Halsey
November 21st 2024
Article

Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes / image credit ©Yi Zhang

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

Grace Halsey
November 18th 2024
Article

AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?

Patient Care Editorial Staff
October 29th 2020
Podcast

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report / image credit American Heart Association

Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report

Grace Halsey
November 11th 2024
Article

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke / image credit American Heart Association

Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke

Grace Halsey
November 11th 2024
Article

AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.

© 2024 MJH Life Sciences

All rights reserved.